Business
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time.
About this update from Evofem Biosciences, Inc.
[{"type":"text","content":"\nAditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a virtual fireside chat set for October 28, 2024, at 11:30 AM Eastern Time. The event will be hosted by Amro Albanna, Co-Founder and CEO of Aditxt, featuring Saundra Pelletier, CEO of Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), and will be moderated by renowned physician and television personality Dr. Drew Pinsky.\n\nThis virtual fireside chat aims to provide an update on Aditxt’s acquisition of Evofem, outline post-acquisition plans, and discuss why Aditxt’s approach to accelerating innovations enables its programs to meet unmet health needs. During the session, Albanna and Pelletier will explore the potential to enhance the strategic vision for Evofem post-acquisition and how Aditxt’s support strategic, operational, and financial contributions, which seek to put Evofem in a position to achieve its goals.\n\nUnder Pelletier's leadership, Evofem is at the forefront of addressing these issues by advancing pioneering solutions like Phexxi® (lactic acid, citric acid and potassium bitartrate) —the only FDA-approved, hormone-free, on-demand contraceptive vaginal gel. The fireside chat will highlight the support of the Aditxt platform and Evofem's evolution into a multi-product women’s health franchise focusing on prevention, treatment, and monitoring. A key milestone in this journey has been Evofem’s acquisition of the global rights to Solosec® (secnidazole), an FDA-approved medication for treating trichomoniasis and bacterial vaginosis. The Evofem commercial team is preparing for the U.S. market re-launch of Solosec®, seeking to position it as a cornerstone in its treatment portfolio.\n\nAdditionally, the collaboration between Aditxt’s subsidiary, Pearsanta, Inc. (“Pearsanta”) and Evofem to launch the Mitomic Endometriosis Test (MET™) would be a significant step in establishing Evofem’s diagnostic and monitoring capabilities. Targeting a U.S. launch in mid-2025, this non-invasive test utilizes cutting-edge biomarkers and has the potential to transform the management of endometriosis. With an estimated one in ten women globally affected by endometriosis, ...